$2.98
+0.14 (+4.93%)
Open$2.84
Previous Close$2.84
Day High$3.03
Day Low$2.82
52W High$7.80
52W Low$1.31
Volume—
Avg Volume780.3K
Market Cap200.99M
P/E Ratio—
EPS$-1.30
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,207.7% upside
Current
$2.98
$2.98
Target
$38.97
$38.97
$29.17
$38.97 avg
$44.78
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.00M | 76.19M | 65.35M |
| Net Income | -1,399,615 | -1,371,226 | -1,459,846 |
| Profit Margin | -1.8% | -1.8% | -2.2% |
| EBITDA | -1,495,155 | -1,465,448 | -1,363,438 |
| Free Cash Flow | -1,111,108 | -1,336,142 | -1,081,347 |
| Rev Growth | +16.0% | +7.1% | -1.4% |
| Debt/Equity | 0.13 | 0.12 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |